SEC Comment Letter for Xtant Medical Holdings, Inc. (XTNT) (CIK 0001453593) (XTNT) — Sep 28, 2010
Xtant Medical Holdings, Inc. (XTNT) (CIK 0001453593)
Date: Sept. 28, 2010 · CIK: 0001453593 · Accession: 0000000000-10-056855
AI Filing Summary & Sentiment
File numbers found in text: 333-158426
Show Raw Text
September 28, 2010 John Gandolfo Chief Financial Officer Bacterin Internati onal Holdings, Inc. 600 Cruiser Lane Belgrade, MT 59714 Re: Bacterin International Holdings, Inc. Item 4.01 Form 8-K Filed September 24, 2010 File No. 333-158426 Dear Mr. Gandolfo: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter within fi ve business days by amending your filing, by providing the requested information, or by advi sing us when you will provide the requested response. If you do not believe our comments apply to your fact s and circumstances or do not believe an amendment is appropriate, pl ease tell us why in your response. After reviewing any amendment to your filing and the information you provide in response to these comments, we ma y have additional comments. Item 4.01 Form 8-K Filed September 24, 2010 1. Please revise paragraph (a)(ii) to disclose whether Uniack’s reports on the financial statements for either of the years ended December 31, 2008 and 2009 contained an adverse opinion or a disclaimer of opini on or were qualified or modified as to uncertainty, audit scope, or accounting principl es and describe the nature of each such adverse opinion, disclaimer of opinion, modification, or qualif ication. Refer to paragraph (a)(1)(ii) of Item 304 of Regulation S-K. In this regar d, we note that Uniack’s report on your financial statements for the year ende d December 31, 2008 cont ained an explanatory paragraph regarding your ability to continue as a going concern. 2. Please file an updated letter from Uniack as an exhibit to th e amendment filed in response to our comments in accordance with Items 304( a)(3) and 601(b)(16) of Regulation S-K. John Gandolfo Bacterin Internati onal Holdings, Inc. September 28, 2010 Page 2 We urge all persons who are responsible for th e accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules requir e. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In responding to our comments, please provi de a written statement from the company acknowledging that: • the company is responsible for the adequacy an d accuracy of the disclo sure in the filing; • staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and • the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. You may contact Lisa Sellars at 202-551-3348 if you have questions. In her absence you may contact me at (202) 551-3344. Sincerely, William H. Thompson Accounting Branch Chief